136703-59-8

Basic information

• Product Name: Butanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-4-hydroxy-, Methyl ester, (3S)-
• Synonyms: Butanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-4-hydroxy-, Methyl ester, (3S)-;N-Boc-β-L-HomoSer-OMe;(3S)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-4-hydroxy-butanoic Acid Methyl Ester
• CAS NO: 136703-59-8
• Molecular Formula: C₁₀H₁₉NO₅
• Molecular Weight: 233.26156
• EINECS: -0
• Mol File: 136703-59-8.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 364.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.125±0.06 g/cm3(Predicted)
• PKA: 11.25±0.46(Predicted)
• CAS DataBase Reference: Butanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-4-hydroxy-, Methyl ester, (3S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-4-hydroxy-, Methyl ester, (3S)-(136703-59-8)
• EPA Substance Registry System: Butanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-4-hydroxy-, Methyl ester, (3S)-(136703-59-8)

Safety Data

• Hazardous Substances Data: 136703-59-8(Hazardous Substances Data)

Usage

Uses

(3S)?-3-[[(1,1-Dimethylethoxy)?carbonyl]?amino]?-4-hydroxy-butanoic Acid Methyl Ester is used to prepare CCR3 antagonists with picomolar inhibition potency against eosinophil chemotaxis. It is also used to synthesize aryl substituted, β- and γ-amino acids in DMF using functionalized zinc reagents.

Upstream product

• 59768-74-0 (S)-2-t-butoxycarbonylaminosuccinic acid 4-methyl ester 
• 543-27-1 isobutyl chloroformate 
• 83345-44-2 3-tert-butoxycarbonylamino-4-hydroxy-butyric acid 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 79069-16-2 benzyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoate 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 67-56-1 methanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 17585-59-0 L-aspartic acid hydrochloride 
• 6384-18-5 L-Aspartic acid dimethyl ester 
• 2177-62-0 β-methyl L-aspartate 
• 139519-25-8 Boc-L-Asp(β-methyl)-N-hydroxysuccinimide 

Downstream Products

• 108149-63-9 tert-butyl (4S)-4-(hydroxymethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 1231672-20-0 tert-butyl [(4R)-2,2-dimethyl-4-(iodomethyl)-1,3-oxazolidin-3-yl]carboxylate 
• 95715-87-0 (R)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyloxazolidine 
• 1302579-22-1 (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester 
• 1302579-68-5 C₂₀H₂₇NO₅ 
• 660852-86-8 (4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 
• 159877-47-1 methyl 3-(R)-[N-(tert-butoxycarbonyl)amino]-propanoate 
• 1416253-42-3 tert-butyl (4-hydroxy-4-methyl-1-(2-oxodihydrofuran-3-ylidene)pentan-2-yl)carbamate 

Relevant articles and documents

Click glycoconjugation of per-azido- and alkynyl-functionalized β-peptides built from aspartic acid

Azide- and alkynyl-containing homo-β3-peptides, of up to six residues in length, were synthesised in solution from aspartic acid. Their subsequent conjugation with monosaccharides bearing an azide or a terminal alkyne function was efficiently achieved by copper-mediated cycloadditions leading to two novel families of small glycoclusters. These compounds represent ideal tools to explore carbohydrate-mediated multivalent interactions.

Synthesis of a chiral β-amino acid derivative by a cobalt-catalysed coupling reaction

A chiral β-amino acid derivative was synthesised by a cobalt-catalysed alkylation of 2,4,5-trifluorophenyl magnesium bromide with the alkyl halide derivative of L-aspartic acid, using an efficient catalytic reagent: CoCl 2/TMEDA. The halide der

PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

[Problem] The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. [Solution] The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects: wherein ring A is C6-10 aryl or the like; X is CR4a or the like; R1 and R2 are a hydrogen atom or the like; R3 is a hydrogen atom or the like; R4 is a hydrogen atom or the like; ring B is C6-10 aryl or the like; R5 is a hydrogen atom or the like; R6a is a hydrogen atom or the like; R7a is a hydrogen atom or the like; R7b is a hydrogen atom or the like; R6b is a hydrogen atom or the like; R8 is a hydrogen atom or the like; n is 0, 1 or 2. Therefore, the compound represented by the formula (I) of the present invention or a pharmaceutically acceptable salt thereof is useful as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

Method for producing pyrazole derivative

PROBLEM TO BE SOLVED: To provide a method for producing a pyrazole derivative. SOLUTION: There is provided the method for producing a pyrazole derivative by using a compound represented by formula (IIC), (IID) or (III) and a compound represented by formula (IV). SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT